Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $23.89.

KURA has been the topic of several research analyst reports. Barclays dropped their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. UBS Group cut their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Tuesday, April 8th. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a report on Tuesday, April 29th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th.

Kura Oncology Stock Performance

Shares of NASDAQ KURA traded down $0.10 during mid-day trading on Friday, reaching $5.90. 161,831 shares of the company's stock were exchanged, compared to its average volume of 1,165,181. The firm has a 50-day moving average price of $6.60 and a two-hundred day moving average price of $9.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market capitalization of $510.79 million, a price-to-earnings ratio of -2.50 and a beta of 0.50. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. Analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares during the period. Franklin Resources Inc. raised its holdings in shares of Kura Oncology by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after acquiring an additional 23,113 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after acquiring an additional 3,092 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after purchasing an additional 2,076 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Kura Oncology in the fourth quarter worth approximately $436,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.